Given the unclear optimal front‐line treatment for patients with advanced BRAF V600 mutated melanoma, we retrospectively compared the overall survival of these patients with front‐line aPD‐1, niv/ipi, or BRAF/MEKi. This evidence concerns the gene BRAF and melanoma.